SCHEMBL29318293

SCHEMBL29318293

COc1cc2nn(C)cc2cc1C(C)C

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.40
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 2/20 0.40
NSD2 O96028 1/20 0.40
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
GFER P55789 1/20 0.39
P2RX3 P56373 7/20 0.38
P2RX2 Q9UBL9 7/20 0.38
IRAK4 Q9NWZ3 1/20 0.34
PDE3B Q13370 1/20 0.34
PDE3A Q14432 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
JAK3 P52333 1/20 0.34
P2RX7 Q99572 2/20 0.33
NQO2 P16083 1/20 0.33
PDE10A Q9Y233 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22946630 0.83 ALDH1A1 (0.47) MAPTALDH1A1KDM4ENSD2GAA
SCHEMBL19531676 0.78 ALDH1A1 (0.43) MAPTALDH1A1KDM4ENSD2
SCHEMBL24163749 0.78 MAPT (0.43) MAPTALDH1A1KDM4ENSD2POLB
SCHEMBL16432372 0.77 AXL (0.42) MAPTALDH1A1KDM4ENSD2JAK3
SCHEMBL24930081 0.77 KDM4E (0.42) MAPTALDH1A1KDM4ENSD2
SCHEMBL26768229 0.77 MAPT (0.42) MAPTALDH1A1KDM4ENSD2POLB
SCHEMBL24255256 0.77 MAPT (0.42) MAPTALDH1A1KDM4ENSD2
SCHEMBL24033484 0.77 ALDH1A1 (0.50) MAPTALDH1A1KDM4ENSD2POLB
SCHEMBL26482518 0.77 MAPT (0.42) MAPTALDH1A1KDM4ENSD2
SCHEMBL25818996 0.77 KDM4E (0.42) MAPTALDH1A1KDM4ENSD2P2RX3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239811-A1 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T REMIX THERAPEUTICS INC. 2024-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239811-A1 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T HNRNPAB, HNRNPC, HNRNPA1 MAPT 2035/4885ALDH1A1 959/4885KDM4E 2019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.